![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis Initiates Comparative-Arm Phase 2 Study of Azixa(TM) for the Front-Line Treatment of Glioblastoma Multiforme
22 déc. 2010 16h19 HE
|
Myrexis, Inc.
SALT LAKE CITY, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis Reports Anti-Tumor Activity in a Subset of Patients From Ongoing Phase 2 Azixa(TM) Study in Recurrent Glioblastoma Multiforme at Society for Neuro-Oncology
19 nov. 2010 09h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 19, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis to Present at Piper Jaffray Health Care Conference
18 nov. 2010 09h20 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 18, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis Presents Data on Cancer Metabolism Inhibitor at 22nd EORTC/NCI/AACR Symposium
17 nov. 2010 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis Reports First Quarter Fiscal 2011 Financial Results
09 nov. 2010 16h21 HE
|
Myrexis, Inc.
AzixaTM Two-Arm Phase 2b Study in Glioblastoma to Begin by Calendar Year-End
Received ~$1.2M Section 48D Tax Grant
Conference Call Today at 4:30pm EST
Upcoming Events
Initiate two-arm...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis Presents Oral Anti-Interferon Data at American College of Rheumatology/Association of Rheumatology Health Professionals
08 nov. 2010 07h55 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 8, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis to Hold Conference Call to Discuss Fiscal First Quarter 2011 Financial Results and Azixa(TM) Phase 2b Study Plans
28 oct. 2010 09h15 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 28, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis to Present Updated Results From Ongoing Phase 2 Azixa(TM) Study in Glioblastoma Multiforme at Society for Neuro-Oncology
21 oct. 2010 14h38 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 21, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis to Present Oral Anti-Interferon Program at American College of Rheumatology/Association of Rheumatology Health Professionals
06 oct. 2010 14h54 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 6, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
![Myrexis, Inc. Logo](/news-release/logo/218223/0/218223.jpg?lastModified=12%2F09%2F2016%2023%3A03%3A24&size=2)
Myrexis Presents Key Findings From Its Cancer Metabolism Inhibitor, MPC-9528
20 sept. 2010 07h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...